BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1363 related articles for article (PubMed ID: 9669384)

  • 1. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
    Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
    J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT.
    Booij J; Hemelaar TG; Speelman JD; de Bruin K; Janssen AG; van Royen EA
    J Nucl Med; 1999 May; 40(5):753-61. PubMed ID: 10319746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional morphometry of the striatum in Parkinson's disease on three-dimensional surface display of 123I-beta-CIT SPECT data.
    Ichise M; Kim YJ; Erami SS; Ballinger JR; Vines D; Tanaka F; Lang AE
    J Nucl Med; 1999 Apr; 40(4):530-8. PubMed ID: 10210210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB
    J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
    Lorberboym M; Djaldetti R; Melamed E; Sadeh M; Lampl Y
    J Nucl Med; 2004 Oct; 45(10):1688-93. PubMed ID: 15471834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.
    Ishikawa T; Dhawan V; Kazumata K; Chaly T; Mandel F; Neumeyer J; Margouleff C; Babchyck B; Zanzi I; Eidelberg D
    J Nucl Med; 1996 Nov; 37(11):1760-5. PubMed ID: 8917170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease.
    Booij J; Tissingh G; Winogrodzka A; Boer GJ; Stoof JC; Wolters EC; van Royen EA
    Eur J Nucl Med; 1997 Jan; 24(1):68-71. PubMed ID: 9044880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
    Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
    Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT.
    Tissingh G; Bergmans P; Booij J; Winogrodzka A; van Royen EA; Stoof JC; Wolters EC
    J Neurol; 1998 Jan; 245(1):14-20. PubMed ID: 9457623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism.
    Booij J; Speelman JD; Horstink MW; Wolters EC
    Eur J Nucl Med; 2001 Mar; 28(3):266-72. PubMed ID: 11315592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake.
    Benamer HT; Patterson J; Wyper DJ; Hadley DM; Macphee GJ; Grosset DG
    Mov Disord; 2000 Jul; 15(4):692-8. PubMed ID: 10928580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.
    Wenning GK; Donnemiller E; Granata R; Riccabona G; Poewe W
    Mov Disord; 1998 May; 13(3):438-45. PubMed ID: 9613734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects.
    Kim HJ; Im JH; Yang SO; Moon DH; Ryu JS; Bong JK; Nam KP; Cheon JH; Lee MC; Lee HK
    J Nucl Med; 1997 Nov; 38(11):1703-11. PubMed ID: 9374337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report.
    Di Giuda D; Calcagni ML; Totaro M; Cocciolillo F; Piano C; Soleti F; Fasano A; Cioni B; Bentivoglio AR; Giordano A
    Nucl Med Commun; 2012 Sep; 33(9):933-40. PubMed ID: 22735298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease.
    Asenbaum S; Brücke T; Pirker W; Podreka I; Angelberger P; Wenger S; Wöber C; Müller C; Deecke L
    J Nucl Med; 1997 Jan; 38(1):1-6. PubMed ID: 8998140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm.
    Habraken JB; Booij J; Slomka P; Sokole EB; van Royen EA
    J Nucl Med; 1999 Jul; 40(7):1091-7. PubMed ID: 10405125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms.
    Filippi L; Manni C; Pierantozzi M; Brusa L; Danieli R; Stanzione P; Schillaci O
    Nucl Med Commun; 2005 May; 26(5):421-6. PubMed ID: 15838424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.